4//SEC Filing
Hammond Janet MJ 4
Accession 0000950170-24-010967
CIK 0001593899other
Filed
Feb 1, 7:00 PM ET
Accepted
Feb 2, 9:24 PM ET
Size
10.9 KB
Accession
0000950170-24-010967
Insider Transaction Report
Form 4
Hammond Janet MJ
Chief Development Officer
Transactions
- Sale
Common Stock
2024-02-01$3.84/sh−14,029$53,913→ 35,362 total - Award
Stock Option (Right to Buy)
2024-01-31+225,200→ 225,200 totalExercise: $4.16Exp: 2034-01-30→ Common Stock (225,200 underlying) - Exercise/Conversion
Restricted Stock Units
2024-01-31−46,800→ 93,600 total→ Common Stock (46,800 underlying) - Exercise/Conversion
Common Stock
2024-01-31+46,800→ 49,391 total
Footnotes (5)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]Includes 2,591 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.
- [F3]Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 14, 2022.
- [F4]The original grant of 140,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.
- [F5]The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028.
Documents
Issuer
Atea Pharmaceuticals, Inc.
CIK 0001593899
Entity typeother
Related Parties
1- filerCIK 0001829899
Filing Metadata
- Form type
- 4
- Filed
- Feb 1, 7:00 PM ET
- Accepted
- Feb 2, 9:24 PM ET
- Size
- 10.9 KB